Ballenger JC, Burrows GD, DuPont RL, et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial I: Efficacy in short-term treatment. Arch Gen Psychiatry. 1988;45(5):413-422.
Ballenger JC, Peterson GA, Laraia M, et al. A study of plasma catecholamines in agoraphobia and the relationship of serum tricyclic level to treatment response in biology of agoraphobia. In: Ballenger JC, ed. Biology of Agoraphobia. Washington: American Psychiatric Press; 1984.
Barlow DH, Cohen AS, Waddell MT, et al. Panic and generalized anxiety disorders: nature and treatment. Behavior Therapy. 1984;15(5):431-449.
Barlow DH, Craske MG, Cerny JA, Klosko JS. Behavioral treatment of panic disorder. Behavior Therapy. 1989;20(2):261-282.
lack DW, Wesner R, Bowers W, Gabel J. A comparison of fluvoxamine, cognitive therapy and placebo in the treatment of panic disorder. Arch Gen Psychiatry. 1993;50(1):44-50.
Charney DS, Woods SW. Benzodiazepine treatment of panic disorder: a comparison of alprazolam and lorazepam. J Clin Psychiatry. 1989;50(11):418-423.
Clark DM, Salkovskis PM, Hackmann A, et al. A comparison of cognitive therapy, applied relaxation and imipramine in the treatment of panic disorder. Br J Psychiatry. 1994;164(6):759-769. See comments.
Coplan JD, Pine DS, Papp LO, Gorman JM. An algorithm-oriented treatment approach for panic disorder. Psychiatry Ann. 1996;26:192-201.
Coplan JD, Tiffon L, Gorman JM. Therapeutic strategies for the patients with treatment-resistant anxiety. J Clin Psychiatry. 1993;54(Suppl):69-74.
Cox BJ, Norton GR, Dorward J, Fergusson PA. The relationship between panic attacks and chemical dependency. Addict Behav. 1989;14(1):53-60.
Den Boer JA, Westenberg HG. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind placebo controlled study with fluvoxamine and maprotiline. Int Clin Psychopharmacol. 1983;3(1):59-74.
Den Boer JA, Westenberg HG. Serotonin function and panic disorder: a double-blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology (Berl). 1990;102(1):85-94.
Fyer AJ, Sandberg D. Pharmacologic treatment of panic disorder. American Psychiatric Press Review of Psychiatry, Vol. 7. Washington: American Psychiatric Press; 1988.
Fyer AJ, Liebowitz MR, Gorman JM, et al. Comparative discontinuation of alprazolam and imipramine in panic patients. Presented at the 27th ACNP Meeting. 1988; San Juan, Puerto Rico.
Goldstein JA. Calcium-channel blockers in the treatment of panic disorder. J Clin Psychiatry. 1985;46(12):546.
Gorman JM, Liebowitz MR, Fyer AJ, et al. An open trial of fluoxetine in the treatment of panic at-tacks. [Published erratum appears in J Clin Psycho-pharmacol. 1988;8(1):13.] J Clin Psychopharma-col. 1987;7(5):329-332.
Harvey AT, Preskorn SH. Interactions of serotonin reuptake inhibitors with tricyclic antidepressants. Arch Gen Psychiatry. 1995;52(9):783-785.
Hoehn-Saric R, Merchant AF, Keyser ML, Smith VK. Effects of clonidine on anxiety disorders. Arch Gen Psychiatry. 1981;38(11):1278-1282.
Kalus O, Asnis GM, Rubinson E, Kahn R, et al. Desipramine treatment in panic disorder. J Affect Disord. 1991;21(4):239-244.
Klein DF. Anxiety reconceptualized. In: Klein DF and Rabkin J, eds. Anxiety, New Research and Changing Concepts. New York: Raven Press; 1981.
Klein DF, Fink M. Psychiatric reaction patterns to imipramine. Am J Psychiatry. 1962;119:432-438.
Klein E, Uhde TW. Controlled study of verapamil for treatment of panic disorder. Am J Psychiatry. 1988;145(4):431-434.
Liebowitz MR, Fyer AJ, McGrath PJ. Clonidine in the treatment of panic disorder. Psychopharmacol Bull. 1981;17:122-123.
Liebowitz MR, Fyer AJ, Gorman JM, et al. Lac-tate provocation of panic attacks. I. Clinical and behavioral findings. Arch Gen Psychiatry. 1984;41 (8):764-770.
Lum M, Fontaine R, Elie R, Ontiveros A. Divalproex sodiums antipanic effect in panic disorder: a placebo controlled study. Biol Psychiatry. 1990;27:164A-165A.
Lydiard RB. Desipramine in agoraphobia with panic attacks: an open fixed-dose study. J Clin Psychopharmacol. 1987;7(4):258-260.
Lydiard RB, Lesser IM, Ballenger JC, et al. A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg and placebo in panic disorder. J Clin Psychopharmacol. 1992;12(2):96-103.
Mavissakalian M. Relationship of dose/plasma concentration on imipramine to the treatment of panic disorder with agoraphobia. In: Ballenger JC, ed. Clinical Aspects of Panic Disorder. New York: Wiley-Liss; 1990.
Nagy LM, Morgan CA 3d, Southwick SM, Charney DS. Open prospective trial of fluoxetine for posttraumatic stress disorder. J Clin Psychopharmacol. 1993;13(2):107-113.
Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry. 1996;153(3):311-320.
Oehrberg S, Christiansen PE, Behnke K, et al. Paroxetine in the treatment of panic disorder. A randomized double-blind placebo-controlled study. Br J Psychiatry. 1995;167(3):374-379.
Paykel ES, Rowan PR, Parker RR, Bhat AV. Response to phenelzine and amitriptyline in subtypes of outpatient depression. Arch Gen Psychiatry. 1982;39(9):1041-1049.
Peselow ED, Lowe RS, Guardino M. The longitudinal course of panic disorder. Presented at the ANCP Meeting. December 1995; San Juan, Puerto Rico.
Preskorn SH, Alderman J, Chung M, et al. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol. 1994;14(2):90-98.
Raj A, Sheehan DV. Medical evaluation of panic attacks. J Clin Psychiatry. 1987;48(8):309-313.
Raj A, Sheehan DV. Somatic treatment strategies in panic disorder. In: Asnis GM, van Praag FIM, eds. Panic DisorderClinical, Biological & Treatment Aspects. New York: John Wiley & Sons; 1995.
Ravaris CL, Nies A, Robinson DS, et al. A mul-tiple-dose controlled study of phenelzine in depression-anxiety states. Arch Gen Psychiatry. 1976;33(3):347-350.
Rickels K, Case WG, Downing RW, Fridman R. One-year follow-up of anxious patients treated with diazepam. J Clin Psychopharmacol. 1986;6(1):32-36.
Robins LN, Regier DA, eds. Psychiatric Disorders in America. New York: Free Press; 1991.
Robinson DS, Nies A, Ravaris CL, Lamborn KR. A monoamine oxidase inhibitor, phenelzine, in the treatment of depressive-anxiety states. A controlled clinical trial. Arch Gen Psychiatry. 1973;29(3):407-413.
Ross HE, Glaser FB, Germanson T. The prevalence of psychiatric disorders in patients with alcohol and other drug problems. Arch Gen Psychiatry. 1988;45(11):1023-1031.
Schneier FR, Liebowitz MR, Davies SO, et al. Fluoxetine in panic disorder. J Clin Psychopharmacol. 1990;10(2):119-121.
Sheehan DV, Ballenger J, Jacobsen G. Treatment of endogenous anxiety with phobic, hysterical and hypochondriacal symptoms. Arch Gen Psychiatry. 1980;37(1):51-59.
Tondo L, Burrai C, Scamonatti L, et al. Carbamazepine in panic disorder. Am J Psychiatry. 1989;146(4):558.
Tyrer P. Risks of dependence on benzodiazepine drugs: the importance of patient selection. BMJ. 1989;298(6666):102,104-105.
Uhde TW, Stein MB, Post RM. Lack of efficacy of carbamazepine in the treatment of panic disorder. Am J Psychiatry. 1988;145(9):1104-1109.
Uhlenhuth EH, DeWit H, Balter MB, et al. Risks and benefits of long-term benzodiazepine use. J Clin Psychopharmacol. 1988;8(3):161-167.
West ED, Dally PJ. The effects of iproniazid in depressive syndromes. BMJ. 1959;1:1491-1494.
Wetzler S, Sanderson WC. In: Asnis GM and van Praag I-/M, eds. Panic DisorderClinical, Biological & Treatment Aspects. New York: John Wiley & Sons; 1995.
Woodman CL, Noyes R Jr. Panic disorder: treatment with valproate. J Clin Psychiatry. 1994; 55(4):134-136.
Psychiatric Times - Category 1 Credit
To earn Category 1 credit,
read the article, "Pathological Gambling: Recognition and Intervention." Complete the application for credit
and mail with your $10 payment to CME LLC You must keep your own records of this activity. Copy this information and include it in your continuing education file for reporting purposes.
CME LLC is accreditied by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. CME LLC designates this article for up to one hour of Category 1 credit for the Physician's Recognition Award of the American Psychiatric Association, when used and completed as designed.
CME LLC invites physicians to take this posttest for Category 1 credit.
- All of the following medical conditions are considered part of the differential diagnosis of panic disorder except:
a. coronary artery disease
b. metastatic cancer
c. irritable bowel syndrome
e. vestibular dysfunction
- Select the correct statement
a. Tricyclic antidepressants are generally considered the treatment of choice in panic disorder.
b. Paroxetine (Paxil), which was recently approved by the FDA for the treatment of panic disorder, has been shown to be clearly more efficacious than sertraline (Zoloft) or fluoxetine (Prozac) in reducing the frequency of panic attacks.
c. Double-blind studies have confirmed the efficacy of the antidepressant/benzodiazepine combination in the initial treatment of panic disorder.
d. Despite adequate pharmacologic treatment, panic disorder is a lifelong illness and as many as 50% of individuals will have relapses.
e. Cognitive behavioral treatment has clearly been shown to be inferior to drug therapy in the treatment of panic disorder.
- A panic attack may be characterized by all of the following symptoms except:
- All of the following statements are true except:
a. In the initial treatment of panic disorder it is best to start at a low dose of medication to avoid side effects such as palpitations and agitation, which may frighten the patient and mimic a panic attack.
b. Depression, social phobia, and substance abuse are often comorbid in panic disorder patients.
c. Long-term usage of benzodiazepines in the treatment of panic disorder is never indicated.
d. At least one-third of individuals with panic disorder develop avoidance (agoraphobia) to places where previous panic attacks have begun.
e. The rationale for using a benzodiazepine/antidepressant combination in the initial phase of panic disorder is that the benzodiazepine will work quickly on the anticipatory anxiety while antidepressants act more slowly to block the panic attacks and also alleviate comorbid depressive symptoms when present.
Click for the answers.